| Author |
Polymorphism |
Disease |
Drug investigated |
Response to drug |
| Louis et al. [37] |
TNF-α -308 A/G |
CD |
Infliximab |
No influence |
| Mascheretti et al. [39] |
Homozygous mutant G-allele at position TNFR2 +587 |
CD |
Infliximab |
Worse response |
| Pierik et al. [40] |
TNFR1 +36 |
Inflammatory bowel disease |
Infliximab |
Worse response |
| Urcelay et al. [41] |
IBD5 polymorphisms |
Inflammatory bowel disease |
Infliximab |
Lack of response |
| Guis et al. [42] |
TNF-α -308 G/G genotype |
RA |
Etanercept |
Better response |
| Maxwell et al. [43] |
TNF-α -308 A/A genotype |
RA |
Etanercept |
Worse response |
| Schmeling and Horneff [44] |
TNF-α -308 A/A genotype |
juvenile idiopathic arthritis |
Etanercept |
Worse response |
| Cuchacovich et al. [46] |
TNF-α -308 genotype |
RA |
Infliximab |
No influence |
| Mugnier et al. [47] |
TNF-α -308 G/G genotype |
RA |
Infliximab |
Better response |
| Fonseca et al. [48] |
TNF-α -308 G/G genotype |
RA |
Infliximab |
Better response |
| Padyukov et al. [51] |
TNF-α -308 G/G
IL-10-1087G/G |
RA |
Etanercept |
Better response |
| Kang et al. [52] |
TNF-α -857 C/T |
RA |
Etanercept |
Better response |
| Criswell et al. [53] |
HLA-DRB1*0404 and *0101 |
RA |
Etanercept |
Better response |
| Soto et al. [55] |
TNF-α -308 TNF-α G/G genotype |
RA |
Adalimumab |
Better response |
| Barreiro-de Acosta et al. [56] |
NOD2, CD14, TLR4 |
CD |
Adalimumab |
No influence |
| Potter et al. [57] |
TLR and NFκB, MyD88 and CHUK |
|
Etanercept |
Better response |
| Jancic et al. [61] |
-174 G/G IL-6 gene polymorphism |
RA |
Etanercept |
Better response |
| Tejasvi et al. [63] |
G allele of SNP rs610604 and T allele of SNP rs2230926 in TNFAIP3 |
Ps |
Etanercept, infliximab, adalimumab |
Better response |
| Tan et al. [65] |
G allele at rs10865035 in AFF3 |
RA |
Etanercept, infliximab, adalimumab |
Better response |
